Novo hemophila drug approved

Share this article:

The FDA approved Novo Nordisk's Hemophilia A drug Novoeight. The Danish drug maker said in a statement Wednesday that it expects to have the drug on the US market during 2015's second quarter.

The treatment is for a type of hemophilia that typically affects men, and is the result of a missing or malfunctioning factor VIII protein.

The drug was among an elite list of medications approved during the government's 16-day shutdown.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters